Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paliperidone + sertraline
- Development stage
- Preclinical
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A combination therapy of paliperidone (an atypical antipsychotic) and sertraline (a selective serotonin reuptake inhibitor). This combination has been studied for treating schizophrenia, showing effectiveness in improving serum neuregulin levels and alleviating negative emotional effects. The mechanism involves paliperidone's antagonism of dopamine D2 and serotonin 5HT2A receptors combined with sertraline's serotonin reuptake inhibition.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)ADRA2A (α2A)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on paliperidone + sertraline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paliperidone + sertraline.